Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.
Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs ...
Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...
The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...
Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...
Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over how to finance the psychedelic company's clinical future.
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback